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patients with false aneurysm located in the thoracic aorta 
and associated with dense adhesions and atelectasis of the 
left lung. A thorough istory should be taken, with special 
attention to previous contact with animals. Serologic 
investigations should include not only tests for syphilis and 
acquired immunodeficiency s ndrome but reaction to 
passive hemaglutination, immunofluorescence assay, and 
enzyme-linked immunosorbent assay, tests specific for 
echinococcosis. 
The absence of e0sinophilia nd other clinical manifes- 
tations of parasitic infection in our patient misled us to 
preclude the presence of hydatid cyst. Fortunately, our 
patient did not show any symptoms of recurrent or 
residual hydatid disease at 14-month follow-up. 
Fig. 2. Dilation of aorta and degeneration of thoracic 
vertebrae 9 and 10 revealed on computed axial tomogra- 
phy. Arrow indicates free bone sequesters of vertebrae 
and its deteriorated image. 
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BENEFICIAL EFFECT OF SYNTHETIC HUMAN ATRIAL NATRIURETIC POLYPEPTIDE ON RENAL 
FUNCTION IN A PATIENT WITH GIANT ATRIA 
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Takaaki Koshiji, MD, Tadashi Ikeda, MD, Shinichi Nomoto, MD, PhD, and Toshihiko Ban, MD, PhD, Kyoto, Japan 
The atrium has specific granules that contain atrial 
natriuretic polypeptides (ANP), which are secreted from 
the heart and circulate throughout the body as a hormone. 
The main pharmacologic properties of ANP are natriure- 
sis, diuresis, vasorelaxation, and inhibition of aldoste- 
rone. 1 Synthetic ANP is currently available and provides 
beneficial effects in patients with heart failure. In this 
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paper, the case of a patient with giant atria lacking ANP 
is described. The effect of synthetic ANP infusion is 
reported. 
Case report. A 55-year-old woman was transferred to our 
department because of orthopnea nd hepatocardiomegaly 
caused by mitral stenosis and tricuspid regurgitation. She has 
twice previously undergone mitral operation (closed mitral 
commissurot0my at age 21 years and open mitral commis- 
surotomy at age 23 years), and congestive heart failure had 
developed because of recurrent mitral stenosis combined 
with severe tricuspid regurgitation that caused marked en- 
largement of both the left and right atria. The left atrium 
measured 73 mm according to the echocardiogram. The 
plasma concentration of ANP Was less than the detectable 
value (<5.0 pg/ml; normal range, 8 to 32) whereas that of 
aldosterone was extraordinarily high (1731 pg/ml; normal 
range, 57 to 161). Renal function was within normal imits 
with a 0.9 ml/dl creatinine level. 
We first used femorofemoral cardiopulmonary b pass 
(CPB) and approached the heart through a right thora- 
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Fig. 1. PostoPerative course showing hemodynamics, doses of human ANP (HANP) and catecholamine, 
and urine volume (UV). Arrows in the graph of urine volume indicate administration of 20 mg furosemide. 
SAOP, Systolic aortic pressure; SPAP, systolic pulmonary arterial pressure; CI, cardiac index; DOA, 
dopamine; DOB, dobutamine. 
cotomy for fear of injuring the right atrium, the wall of 
which was remarkably thinned. The mitral valve was 
replaced with a Bj6rk-Shiley valve and the enlarged ring 
of the tricuspid valve was repaired with a Carpentier ring. 
The CPB time was 259 minutes, and the weaning process 
from CPB with the assistance of inotropic drugs was 
uncomplicated, The postoperative course was fairly stable 
in terms of hemodynamic parameters with optimal cardiac 
indices. Fig. 1 illustrates the events of the entire postop- 
erative time course. 
About 8 to 12 hours after operation the urine volume 
gradually decreased to 10 to 20 ml/hr despite intravenous 
injection of 20 mg of furosemide. The creatinine level at 
that time was 1.4 mg/dl. We then started intravenous 
infusion of synthetic human alpha-ANP (Carperitide; 
Suntory Inc., Division of Pharmaceuticals, Tokyo, Japan) 
at a rate of 0.05/~g/kg per minute. Thereafter, systolic and 
mean pulmonary arterial pressures decreased from 48 to 
33 mm Hg and from 30 to 24 mm Hg, respectively, 
whereas ystolic aortic pressure remained unchanged. The 
urine volume then dramatically increased to 100 to 120 
ml/hr and this volume was maintained at about that level 
for the next 90 hours until infusion of alpha-ANP was 
discontinued. 
Successful extubation was accomplished 74 hours after 
operation. After cessation of alpha-ANP infusion, pulmo- 
nary arterial pressure increased again and urine volume 
decreased, suggesting that ANP was effective in this 
patient. Four weeks after operation, she received further 
alpha-ANP infusion at the same dosage for 4 days because 
of resistance to conventional diuretics. She recovered fully 
and was discharged from the hospital 3 months later. At 
that time. the plasma concentration fANP was as before 
less than the detectable value. 
Discussion. The special features of this case were 
marked enlargement ofboth the left and right atria and an 
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extraordinarily ow plasma ANP concentration. In gen- 
eral, the plasma ANP concentration shows a graded rise in 
patients with congestive heart failure because atrial dis- 
tention is a key trigger that stimulates ANP secretion. 2 
This patient underwent closed and open mitral commis- 
surotomy more than 30 years ago, at which time the 
appendages must have been removed or ligated. We 
previously reported that the secretory function of ANP 
was impaired after resection of atrial appendages in 
experimental heart failure models. 3 In addition, sustained 
mitral stenosis and tricuspid regurgitation i duced exces- 
sive extension of the atria, which may have further dimin- 
ished the granules producing ANP. Thus it is considered 
that the patient had a lack of ANP secretion despite 
congestive heart failure. 
Infusion of alpha-ANP was notably effective in this 
patient in terms of diuresis and in reducing preload level. 
Saito and associates t first reported the beneficial effect of 
ANP administration i  patients with congestive heart 
failure. We also reported the hemodynamic effects of 
ANP infusion after cardiac operation as cardiac output 
increased and pulmonary arterial pressure decreased. 4 
We recently performed a trial of continuous infusion of 
ANP for more than 24 hours in more than 10 patients 
after cardiac operation irrespective of the plasma ANP 
concentration. In selected patients, ANP infusion mark- 
edly increased urine volume whereas in these patients the 
diuretic effect of furosemide was minimal (unpublished 
data). Continuous infusion of alpha-ANP should be tried 
in patients after cardiac operations when oliguria devel- 
ops. 
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PYODERMA GANGRENOSUM AND MYELOFIBROSIS AFTER CORONARY ARTERY BYPASS 
GRAFTING 
Louis E. Samuels, MD, ~ Marla S. Kaufman, BA, ~ William G. Kussmaul, MD, b and Stanley K. Brockman, MD, a 
Philadelphia, Pa. 
A 66-year-old white man was admitted to the Allegheny 
University Hospitals, Hahnemann Division, Philadelphia, 
in April 1996 with unstable angina and shortness of 
breath. The medical history was significant for coronary 
artery disease, chronic renal failure, and hypertension. On 
admission to the hospital, the white blood cell count was 
8100 per microliter, hemoglobin and hematocrit levels 
were 8.5 gm/dl and 25.1%, and platelet count was 230 
K/UL. Cardiac catheterization 2 days after hospital ad- 
mission showed severe triple-vessel coronary artery dis- 
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ease. Seven days after hospital admission, the patient 
underwent coronary artery bypass grafting. The immedi- 
ate postoperative course was uneventful. 
On postoperative day (POD) 3, fever (101.7 ° F) and 
sternal tenderness with serous drainage developed. The 
white blood cell count was 15 K/UL. Empiric broad-spec- 
trum antibiotic therapy was started. On POD 5, sternal 
wound debridement was done. No signs of gross infection 
were observed. Instead, there was extensive sternal and 
subcutaneous ti sue necrosis. The operative Gram stain test 
showed negative results for organisms and there was no 
growth on culture. Skin and subcutaneous tissue necrosis 
progressed. On POD 6, an abrupt drop in the white blood 
cell and platelet counts occurred (Figs. 1 and 2). Fever and 
pancytopenia persisted over the next couple of days. 
On POD 13, further sternal wound debridement was 
done. Similar findings of necrotic uninfected tissue 
were observed. On POD 19, histopathologic examina- 
tion of the skin specimens was diagnostic of pyoderma 
gangrenosum. Steroid therapy (hydrocortisone 100 mg 
intravenously every 8 hours) was instituted. On POD 
28, the patient underwent a bone marrow biopsy. 
Myelofibrosis was found. Therapy with bone marrow 
